Nurturher Aesthetics explains why most providers aren't using retatrutide, pointing out that the Lilly drug has no FDA approval yet.
Recap by typeshit. Post by @nurturher_aesthetics on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Months after an advisory panel backed easing limits on BPC-157 and others, Medical Daily reviews hospitalizations and Nevada fines over two intubated women.
20:32
Dra. Ana Maria Kausel walks through common errors people make on GLP-1 drugs, covering Ozempic, Mounjaro, Wegovy and Zepbound.
Loading…